Toxicity Testing Outsourcing Market

In vivo toxicity testing is estimated at 41.0% by service type in 2026, with drug development projected at 48.0% and direct contract research services at 52.0% of distribution activity. Evidence continuity supports adoption across regulated programs, although study capacity and method qualification constrain program timing.